fda.gov· FDA·· 6 hours agoScore40
Verified Clinical Benefit | Cancer Accelerated Approvals
Verified Clinical Benefit | Cancer Accelerated Approvals
In brief
The FDA lists oncology accelerated approvals that have since had clinical benefit verified, spanning drugs from Keytruda and Opdivo to Tecvayli and Imdelltra. Each entry pairs the original accelerated approval date with its verification date, for example Keytruda in TMB-high solid tumors and Breyanzi in relapsed or refractory follicular lymphoma. The list covers indications across solid tumors and blood cancers, including Retevmo in RET fusion solid tumors, Tecvayli in multiple myeloma and Jaypirca in CLL/SLL.
Source: fda.gov · fda.gov